Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Arrhythmias in 2015

Advances in drug, ablation, and device therapy for cardiac arrhythmias

Nature Reviews Cardiology volume 13, pages 67–68 (2016)Cite this article

Subjects

An Erratum to this article was published on 29 January 2016

This article has been updated

Cardiac arrhythmias produce considerable morbidity and mortality, and are challenging to treat. Advances reported in 2015 will help to guide physicians in the use of therapeutic approaches ranging from established pharmaceutical agents through ablation of arrhythmic sources to novel uses of implanted devices for life-threatening bradyarrhythmias and tachyarrhythmias.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Therapies for cardiac arrhythmias.

Change history

  • 29 January 2016

    In the version of this article initially published online and in print, Figure 1 incorrectly showed the ablation catheter passing through the aorta, instead of directly from the right to the left atrium. The error has been corrected for the HTML and PDF versions of the article.

References

  1. Verma, A. et al. Approaches to catheter ablation for persistent atrial fibrillation. N. Engl. J. Med. 372, 1812–1822 (2015).

    Article  Google Scholar 

  2. Macle, L. et al. Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet 386, 672–679 (2015).

    Article  Google Scholar 

  3. Kobori, A. et al. Adenosine triphosphate-guided pulmonary vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehv457.

  4. Washam, J. B. et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 385, 2363–2370 (2015).

    Article  CAS  Google Scholar 

  5. Chao, T. F. et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 132, 1604–1612 (2015).

    Article  CAS  Google Scholar 

  6. Vamos, M., Erath, J. W. & Hohnloser, S. H. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur. Heart J. 36, 1831–1838 (2015).

    Article  CAS  Google Scholar 

  7. Healey, J. S. et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet 385, 785–791 (2015).

    Article  Google Scholar 

  8. Burke, M. C. et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J. Am. Coll. Cardiol. 65, 1605–1615 (2015).

    Article  Google Scholar 

  9. Reddy, V. Y. et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N. Engl. J. Med. 373, 1125–1135 (2015).

    Article  CAS  Google Scholar 

  10. Reynolds, D. et al. A leadless intracardiac transcatheter pacing system. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1511643.

Download references

Acknowledgements

S.N. is also on the faculty of the Departments of Pharmacology and Therapeutics and Medicine at McGill University, Montreal, Quebec, Canada, as well as the West German Heart and Vascular Center, Faculty of Medicine, University Duisburg–Essen, Essen, Germany.

Author information

Authors and Affiliations

  1. Laurent Macle and Stanley Nattel are at the Department of Medicine, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec H1T 1C8, Canada.,

    Laurent Macle & Stanley Nattel

Authors
  1. Laurent Macle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stanley Nattel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley Nattel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Macle, L., Nattel, S. Advances in drug, ablation, and device therapy for cardiac arrhythmias. Nat Rev Cardiol 13, 67–68 (2016). https://doi.org/10.1038/nrcardio.2015.196

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2015.196

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing